Derek Potts Appointed Liaison Counsel in California Xarelto JCCP Cases

Potts Law Firm Actively Involved in Multiple States Including CA, MO, PA and MDL in LA

News provided by

Jan 16, 2017, 10:29 ET

HOUSTON, Jan. 16, 2017 /PRNewswire/ -- Derek H. Potts, founder and national managing partner of Potts Law Firm, was recently appointed Liaison Counsel in California's Judicial Council Coordinated Proceedings (JCCP) for all Xarelto cases. In this role, Potts was assigned to serve as representative of all plaintiff parties and will actively assist the Court and Co Lead Plaintiff's Counsel. Co-Counsel includes Mark Milstein with Milstein Adelman Jackson Fairchild & Wade and Ruth Rizkalla with Kirtland & Packard.

Derek H. Potts, founder and national partner of Potts Law Firm

Potts has extensive experience representing plaintiffs in multi-district litigation and in pharmaceutical and medical device cases. He has been appointed by multiple courts to upper level plaintiffs' leadership positions in complex litigation and multi-district litigation.

"We understand the important nature of the pharmaceutical litigation given the health issues at hand," said Potts. "We're glad to be of service to our clients in helping them resolve their cases as quickly as possible."

Potts was instrumental in establishing the Consolidated Transvaginal Mesh Multi District Litigation in the U.S. District Court for the Southern District of West Virginia. He was appointed by two federal judges overseeing the mesh litigation to coordinate the consolidations on behalf of 100,000 women making claims against the manufacturers of the mesh products. He has successfully resolved tens of thousands of transvaginal mesh claims for his clients.

Xarelto (rivaroxaban) is an oral anticoagulant (blood thinner) used to prevent blood clot formation in individuals with atrial fibrillation (irregular heartbeat) or those at risk for developing deep vein thrombosis and pulmonary embolism especially after hip or knee replacement surgery. Xarelto inhibits clot formation by blocking a specific clotting protein which is naturally found in the blood.

Xarelto was developed by Bayer and Johnson & Johnson's New Jersey-based unit, Janssen Pharmaceuticals. The potential risk of patients taking Xarelto is severe, and uncontrolled bleeding which can lead to organ damage and even death. Due to the lack of a reversal agent, patients are at further risk of prolonged bleeding without an available remedy.

Widely recognized for his expertise in complex litigation and trials, Potts has obtained record-setting verdicts and settlements on behalf of clients in state and federal courts across the country. He also regularly speaks and lectures to lawyers around the country on topics ranging from trial advocacy to handling complex mass torts matters.

About Potts Law Firm

Potts Law Firm diligently pursues a variety of personal injury claims and mass tort matters, from complex pharmaceutical cases to challenging product liability claims. The firm's team of highly competent attorneys have experience in many different areas of personal injury law. Believing that every detail of a case matters, firm attorneys work tirelessly to pursue just compensation, regardless of the obstacles faced. For more information, visit www.potts-law.com

For more information contact:

Steve Stasny
832-838-4553
[email protected]

SOURCE Potts Law Firm